CytoDyn Inc. CYDY
OTC PK
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.81% | 2.60% | -17.47% | -29.42% | -24.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.82% | 51.04% | 26.78% | 17.25% | 10.80% |
| Operating Income | -39.82% | -51.04% | -26.78% | -17.25% | -10.80% |
| Income Before Tax | -171.60% | -1,240.16% | -447.46% | -172.75% | -10.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -171.60% | -1,240.16% | -447.46% | -172.75% | -10.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -171.60% | -1,240.16% | -447.46% | -172.75% | -10.39% |
| EBIT | -39.82% | -51.04% | -26.78% | -17.25% | -10.80% |
| EBITDA | -39.77% | -51.10% | -26.81% | -17.28% | -10.86% |
| EPS Basic | -143.96% | -1,209.68% | -267.82% | -89.41% | 21.55% |
| Normalized Basic EPS | -41.28% | -25.47% | 0.00% | 23.49% | 34.34% |
| EPS Diluted | -122.12% | -36,100.00% | -291.40% | -107.95% | 12.61% |
| Normalized Diluted EPS | -41.28% | -26.67% | -0.78% | 22.97% | 33.94% |
| Average Basic Shares Outstanding | 6.99% | 6.91% | 9.35% | 14.45% | 20.83% |
| Average Diluted Shares Outstanding | 6.99% | 5.53% | 7.86% | 12.81% | 18.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |